English
- English
- 中文
PanMediso | Science, innovation and technology
PanMediso | Business Areas
Medical Isotope Ac-225 and Applications
As an experimental radiopharmaceutical, Ac-225 and other alpha-particle emitters are gaining attention in cancer therapy. Due to their short tissue penetration range and high energy, alpha particles can precisely target and destroy cancer cells effectively.
- Therapeutic half-life: With a half-life of 10 days, Ac-225 provides sufficient time for therapeutic use while ensuring minimal residual radiation in the body after several months.
- Clinical validation: Multiple clinical trials have demonstrated the efficacy of Ac-225 in targeted alpha therapy (TAT).
- Broad applicability: Ac-225 conjugates (e.g., antibodies labeled with Ac-225) have been tested against various cancers, including leukemia, prostate cancer, and breast cancer.
- Promising results: One Ac-225–based experimental drug has shown significant effectiveness in treating Acute Myeloid Leukemia (AML) without causing harm to patients.
High purity
Low radiation
Resource Efficiency
Cost efficiency
Medical Isotope Ac-225 and Applications
As an experimental radiopharmaceutical, Ac-225 and other alpha-particle emitters are gaining attention in cancer therapy. Due to their short tissue penetration range and high energy, alpha particles can precisely target and destroy cancer cells effectively .
- Therapeutic half-life: With a half-life of 10 days, Ac-225 provides sufficient time for therapeutic use while ensuring minimal residual radiation in the body after several months.
- Clinical validation: Multiple clinical trials have demonstrated the efficacy of Ac-225 in targeted alpha therapy (TAT).
- Broad applicability: Ac-225 conjugates (e.g., antibodies labeled with Ac-225) have been tested against various cancers, including leukemia, prostate cancer, and breast cancer.
- Promising results: One Ac-225–based experimental drug has shown significant effectiveness in treating Acute Myeloid Leukemia (AML) without causing harm to patients.
High purity
Low Radiation
Resource Efficiency
Cost Efficiency
Email: pchl@pamedicholdings.com
Address: Room 406, Building C, Hetao Innovation Center No. 1 Honghua
Road, Fubao Subdistrict Futian District, Shenzhen, China
Copyright@2025 PanMediso
